tiprankstipranks
Trending News
More News >
Geratherm Medical AG (DE:GME)
XETRA:GME
Advertisement

Geratherm Medical (GME) AI Stock Analysis

Compare
8 Followers

Top Page

DE:GME

Geratherm Medical

(XETRA:GME)

Select Model
Select Model
Select Model
Neutral 58 (OpenAI - 4o)
Rating:58Neutral
Price Target:
€7.50
▲(7.45% Upside)
The overall stock score for Geratherm Medical is primarily influenced by its mixed financial performance and technical analysis. The company shows financial stability with low leverage and improving cash generation, but faces significant revenue growth challenges. Technical indicators suggest overbought conditions, which could pose a risk to short-term investors. The valuation is relatively attractive with a low P/E ratio and a modest dividend yield, providing some support to the stock's score.

Geratherm Medical (GME) vs. iShares MSCI Germany ETF (EWG)

Geratherm Medical Business Overview & Revenue Model

Company DescriptionGeratherm Medical AG operates as a medical technology company in Germany. It operates through Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems segments. The Healthcare Diagnostic segment provides clinical thermometers; blood pressure monitors; and self-test diagnostic products for women, including pregnancy tests, chlamydia tests, urinary tract infections, diverse ovulation test solutions, and pH tests. The Respiratory segment develops and manufactures products primarily for pulmonary and cardiopulmonary function diagnostics. The Medical Warming Systems segment offers MRI-compatible incubators for premature and newborn infants under the LMT brand. The Cardio/Stroke segment offers stroke risk analysis products for the detection of atrial fibrillation. The company markets its products through pharmacies, hospitals, and clinics. It exports its products to approximately 60 countries. The company was founded in 1990 and is headquartered in Geschwenda, Germany.
How the Company Makes MoneyGeratherm Medical generates revenue through the sale of its medical devices and diagnostic products to hospitals, clinics, and retail pharmacies. The company has established key revenue streams through direct sales, distribution agreements, and partnerships with healthcare providers and organizations. Additionally, GME focuses on expanding its market presence in emerging economies and leverages research and development to innovate and introduce new products, thus enhancing its competitive edge and driving sales growth.

Geratherm Medical Financial Statement Overview

Summary
Geratherm Medical demonstrates a mixed financial performance. The income statement highlights profitability challenges with declining revenue growth, while the balance sheet shows financial stability with low leverage. The cash flow statement indicates improving cash generation. The company needs to address revenue growth issues while maintaining its strong balance sheet and improving cash flow conversion.
Income Statement
55
Neutral
Geratherm Medical's income statement shows a mixed performance. The TTM (Trailing-Twelve-Months) data indicates a decline in revenue growth rate by 109.5%, which is concerning. However, the company maintains a positive net profit margin of 12.27%, indicating profitability despite revenue challenges. The gross profit margin has decreased over time, reflecting potential cost management issues. Overall, the income statement reflects moderate profitability with significant revenue growth challenges.
Balance Sheet
70
Positive
The balance sheet of Geratherm Medical is relatively strong, with a low debt-to-equity ratio of 0.126 in the TTM, indicating prudent leverage management. The return on equity is modest at 8.38%, suggesting efficient use of equity to generate profits. The equity ratio remains stable, showing a solid equity base. Overall, the balance sheet reflects financial stability with low leverage and moderate returns on equity.
Cash Flow
60
Neutral
Geratherm Medical's cash flow statement shows a positive trajectory in free cash flow growth at 23.03% in the TTM, indicating improved cash generation. The operating cash flow to net income ratio is strong at 3.18, suggesting robust cash flow relative to net income. However, the free cash flow to net income ratio is slightly below 1, indicating that not all net income translates into free cash flow. Overall, the cash flow statement reflects improving cash generation with some areas for further enhancement.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue14.29M20.43M20.96M25.85M24.64M27.47M
Gross Profit5.96M12.78M6.27M6.38M16.32M17.60M
EBITDA-1.94M2.95M4.18M3.37M2.20M4.35M
Net Income1.75M705.17K1.11M1.02M122.23K2.05M
Balance Sheet
Total Assets27.53M28.54M35.72M38.38M34.56M35.99M
Cash, Cash Equivalents and Short-Term Investments9.61M9.64M7.74M10.89M6.47M10.26M
Total Debt2.62M3.28M7.23M9.29M9.32M10.40M
Total Liabilities6.95M7.71M13.11M16.15M15.93M16.07M
Stockholders Equity20.83M21.02M22.33M22.34M18.52M20.30M
Cash Flow
Free Cash Flow2.68M1.23M-212.00K-133.00K-353.00K1.14M
Operating Cash Flow2.79M1.87M1.43M2.61M917.00K3.92M
Investing Cash Flow3.89M3.82M-2.09M-767.00K3.00K-3.79M
Financing Cash Flow-2.43M-2.69M-3.09M4.35M-3.52M684.00K

Geratherm Medical Technical Analysis

Technical Analysis Sentiment
Positive
Last Price6.98
Price Trends
50DMA
3.21
Positive
100DMA
3.18
Positive
200DMA
3.24
Positive
Market Momentum
MACD
0.40
Negative
RSI
96.08
Negative
STOCH
87.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:GME, the sentiment is Positive. The current price of 6.98 is above the 20-day moving average (MA) of 3.38, above the 50-day MA of 3.21, and above the 200-day MA of 3.24, indicating a bullish trend. The MACD of 0.40 indicates Negative momentum. The RSI at 96.08 is Negative, neither overbought nor oversold. The STOCH value of 87.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:GME.

Geratherm Medical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
€38.01M12.588.35%1.43%-23.48%
47
Neutral
€21.28M-4.52-34.70%-0.59%24.03%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:GME
Geratherm Medical
6.98
3.33
91.39%
DE:AAQ1
aap Implantate
1.51
-0.24
-13.71%
DE:B8FK
Biofrontera
2.79
0.41
16.98%
DE:SBX
SynBiotic SE
2.98
-2.94
-49.66%
DE:BIG1
Bio-Gate AG
0.93
0.11
13.41%
DE:E8X
elexxion AG
0.16
-0.16
-50.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 03, 2025